• Selected Projects and Publications

1. Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology–Based Tool to Support and Review Registries
   Value in Health, March 2022
   
   
2. Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA’s Health Technology Assessments
   Value in Health, May 2021
   
   
3. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
   Health Policy, June 2020
   
   
4. Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
   Health Economics Review, December 2019
   
   
5. Analysis of acceptance rate and rationales for rejection of indirect comparisons in IQWiGʼs benefit assessments
   Gesundheitsökonomie & Qualitätsmanagement, May 2019
   
   
6. Effect of crossover in oncology clinical trials on evidence levels in early benefit assessment in Germany
   Value in Health, June 2018
   
   
7. Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
   International Journal of Technology Assessment in Health Care, October 2018
   
   
8. Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
   Health Economics Review, September 2018
   
   
9. “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendation
   Health Economics Review, September 2018
   
   
10. Are FJC appraisals suitable to guide therapeutic decisions?
    Gesundhheitsökonomie & Qualitätsmanagement, September 2018
    
    
11. Different approaches to evidence-based medicine in regulatory, health technology, and clinical decision making
    Pharmaceutical Medicine, July 2017
    
    
12. Formative biology of bee swarms
    Tycho de Brahe Year Book, November 2016
    
    
13. Aristotelian cause – Effect principles in medicine
    Der Merkurstab, April 2016
    
    
14. Comparing EMA post authorization measures and additional evidence requirements by HTA bodies
    Health Economics Review, November 2016
    
    
15. Patient relevance of primary endpoints across various disease areas
    BMC Health Services Research, November 2016
    
    
16. Early benefit assessments in oncology in Germany: How can a clinically relevant endpoint not be relevant to patients?
    Drugs in R&D, August 2015
    
    
17. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
    European Journal of Health Economics, July 2014
    
    
18. Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach
    Value in Health, June 2014
    
    
19. Content comparison of QoL instruments in COPD
    Respiratory Medicine, January 2007
    
    
20. Direct costs in rheumatoid arthritis
    Annals of Rheumatic Diseases, March 2005
    
    
21. ICF core sets for diabetes mellitus
    Journal of Rehabilitative Medicine, August 2004
    
    
22. ICF core sets for obesity
    Journal of Rehabilitation Medicine, August 2004